Cephalon, a wholly owned subsidiary of Teva Pharmaceutical Industries, will market the product.
Provigil will continue to be manufactured under the brand product’s NDA at the same facility where it is currently produced, the company said.
The brand product had annual sales of approximately $1.1bn in the US, according to IMS sales data.